1. Clinical Overview
Fluticasone Propionate is a potent, synthetic, trifluorinated glucocorticoid receptor agonist with high topical anti-inflammatory activity. In its 0.05% w/v formulation, it is primarily used topically for dermatological conditions. It acts by binding to glucocorticoid receptors, inhibiting the release of pro-inflammatory mediators, and suppressing the inflammatory response. It is considered a medium-potency topical corticosteroid in the Indian classification system.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clinical improvement in inflammation and pruritus is typically observed within 3-5 days of starting therapy. | The anti-inflammatory effect persists for several hours after application, necessitating once or twice-daily application as prescribed. | Topical bioavailability is low, estimated at <1-2% on intact skin. Systemic absorption increases significantly with application to inflamed skin, under occlusion, or on large body surface areas. |
2. Mechanism of Action
Fluticasone propionate diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The activated receptor-ligand complex translocates to the nucleus, where it modulates gene transcription. It increases the synthesis of anti-inflammatory proteins (like lipocortin) and decreases the synthesis of pro-inflammatory mediators.
3. Indications & Uses
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., Atopic Dermatitis, Contact Dermatitis, Seborrheic Dermatitis, Eczema)
- Psoriasis (plaque-type, excluding widespread plaque psoriasis)
- Lichen Planus
- Lichen Simplex Chronicus
4. Dosage & Administration
Adult Dosage: Apply a thin film to the affected area once or twice daily, as directed by the physician. Frequency may be reduced once control is achieved.
Administration: Wash and dry the affected area gently. Apply a thin layer and rub in lightly until it disappears. Do not bandage or cover the area unless directed by a doctor. Wash hands after application unless hands are the treated area. Avoid contact with eyes, mouth, nose, and mucous membranes.
5. Side Effects
Common side effects may include:
- Local burning or stinging sensation
- Skin dryness
- Pruritus at application site
- Skin irritation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | May inhibit the metabolism of systemically absorbed fluticasone, increasing the risk of systemic corticosteroid effects and HPA axis suppression. | Moderate |
| Other Topical Corticosteroids | Concomitant use on the same area increases the risk of additive local and systemic side effects. | Moderate |
| Topical Immunosuppressants (e.g., Tacrolimus, Pimecrolimus) | May be used sequentially but concurrent application is generally not recommended without specialist advice. | Low |
7. Patient Counselling
- DO use exactly as prescribed by your doctor.
- DO apply a thin layer only.
- DO wash hands before and after application (unless hands are treated).
- DO report any signs of infection (increased redness, pus, pain) or lack of improvement.
- DON'T use on the face, groin, or underarms unless specifically told to do so.
- DON'T bandage or wrap the treated area unless instructed.
- DON'T use for longer than the prescribed duration.
- DON'T share your medicine with others.
8. Toxicology & Storage
Overdose: Topical overdose manifests as severe local side effects: pronounced skin atrophy, striae, telangiectasia, HPA axis suppression (symptoms: fatigue, weakness, nausea, hypotension, hypoglycemia), and Cushingoid features (moon face, central obesity).
Storage: Store at room temperature (15-25°C). Protect from light and excessive heat. Do not freeze. Keep the tube tightly closed. Keep out of reach and sight of children.